Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gantenerumab in prodromal Alzheimer's disease
2010-019895-66Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gantenerumab in Alzheimer's disease (AD) (3 arms), sponsored by Roche. Primary endpoint: Change in Clinical Dementia Rating scale Sum of Boxes. Started Aug 2010; status: completed.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2010-019895-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019895-66.